







an Open Access Journal by MDPI

# Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy

Guest Editors:

#### Prof. Dr. Michael Chan

Department of Biomedical Sciences, National Chung Cheng University, Chia Yi, Taiwan

## Dr. Peter J. K. Kuppen

Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

Deadline for manuscript submissions:

closed (25 December 2020)

# **Message from the Guest Editors**

Dear Colleagues,

Cancer immunotherapy, such as immune checkpoint blockade, is effective against human cancer. However, only a subset of patients benefit from this novel therapy. It is, therefore, important to explore the mechanism behind this phenomenon. Recent evidence suggest that cancer cells may alter the epigenetic machinery, that controls RNA expression, for instance by DNA methylation and histon modifications, to evade the immune attack. In this special issue, we invite researchers to submit original research articles or reviews to uncover how targeting the epigenetic machinery can enhance cancer immunotherapy in human cancer.

Dr. Peter Kuppen Prof. Michael Chan Guest Editors













an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Ernesto Guccione Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

# **Message from the Editor-in-Chief**

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

*Epigenomes* (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

**Journal Rank:** CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

#### **Contact Us**